| Old Articles: <Older 5991-6000 Newer> |
|---|
 |
The Motley Fool
November 3, 2009
Rich Smith |
Is BABY Back? Natus Medical beat earnings, but can it continue to top the S&P 500?   |
The Motley Fool
November 3, 2009
Brian Orelli |
Amylin Scores a Hat Trick Amylin Pharmaceuticals got a triple dose of good news over the weekend. |
The Motley Fool
November 3, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron. |
The Motley Fool
November 2, 2009
Brian Orelli |
Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed. |
The Motley Fool
November 2, 2009
Brian Orelli |
Winners and Losers of the House Health-Care Reform Bill There's something for everyone to hate. |
The Motley Fool
October 31, 2009
Shannon Zimmerman |
Obamacare PASS! The One Stock to Buy Real reform will create real opportunity in health insurance and medical industry stocks |
The Motley Fool
October 30, 2009
Brian Orelli |
Pfizer Pfires Up Say on Pay It took six months from when shareholders asked for it, but Pfizer's board has finally given shareholders a voice on executive compensation. |
The Motley Fool
October 30, 2009
Brian Orelli |
Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
October 30, 2009
Brian Orelli |
It's Not As Frightening As It First Appears Dig a little, and you'll see that generic-drug maker Mylan is far from a copycat of its struggling branded-drug-making counterparts. |
| <Older 5991-6000 Newer> Return to current articles. |
